EGFR and lung cancer: The remarkable advent of gefitinib in 2000, EGFR tyrosine kinase inhibitor (EGFR-TKI) targeted therapy as a representative precision medicine has facilitated spectacular alterations to the lung cancer study philosophy and treatment model.